Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
JAMA
    March 2026
  1. RUBIN R
    Lithium for Alzheimer Disease-Pilot Study Sets the Stage for Larger Trials.
    JAMA. 2026 Mar 20. doi: 10.1001/jama.2026.3046.
    >> Share

  2. ANDERER S
    Alzheimer Disease Sex Differences May Be Tied to P-Tau217.
    JAMA. 2026 Mar 13. doi: 10.1001/jama.2026.1013.
    >> Share

    January 2026
  3. WHITSON HE, Fowler NR, Mielke MM
    Blood-Based Biomarkers for Alzheimer Disease: Preventing Unintended Consequences.
    JAMA. 2026 Jan 22. doi: 10.1001/jama.2025.26049.
    >> Share

    December 2025
  4. KNOPMAN DS
    Valacyclovir and Symptomatic Alzheimer Disease-No Evidence for Benefit.
    JAMA. 2025 Dec 17. doi: 10.1001/jama.2025.20795.
    >> Share


  5. Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: Research Summary.
    JAMA. 2025 Dec 17:e2522830. doi: 10.1001/jama.2025.22830.
    >> Share

  6. DEVANAND DP, Wisniewski T, Razlighi Q, Qian M, et al
    Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial.
    JAMA. 2025 Dec 17:e2521738. doi: 10.1001/jama.2025.21738.
    >> Share

  7. RUBIN R
    Alzheimer Disease Blood Test Cleared for Primary Care, but Questions Remain About Its Use.
    JAMA. 2025 Dec 5. doi: 10.1001/jama.2025.21573.
    >> Share

    September 2025
  8. ANDERER S
    Alzheimer Disease Exacerbated by Air Pollution, Study Suggests.
    JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.13889.
    >> Share

  9. RUBIN R
    Trying to Unravel Why Alzheimer Disease Is More Common in Women.
    JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.16269.
    >> Share

  10. ANDERER S
    First Antiamyloid Injectable Approved for Early Alzheimer Disease.
    JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.13885.
    >> Share

    August 2025
  11. RUBIN R
    Treating Alzheimer Disease With Antiamyloid Therapies-The Real-World Experience Grows.
    JAMA. 2025 Aug 22. doi: 10.1001/jama.2025.14180.
    >> Share

  12. HUNT V
    An Alzheimer Biomarker Is Elevated in Newborns-Dementia Researchers Want to Know How They Clear It.
    JAMA. 2025 Aug 8. doi: 10.1001/jama.2025.13588.
    >> Share

    July 2025
  13. CHEN KY, Ross JS, Cohen AB, Karlawish J, et al
    Demographic Data Supporting FDA Authorization of AI Devices for Alzheimer Disease and Related Dementias.
    JAMA. 2025 Jul 30:e2512779. doi: 10.1001/jama.2025.12779.
    >> Share

    June 2025
  14. MOSCOSO A, Heeman F, Raghavan S, Costoya-Sanchez A, et al
    Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.
    JAMA. 2025 Jun 16. doi: 10.1001/jama.2025.7817.
    >> Share

  15. RUBIN R
    What to Know About the First FDA-Cleared Blood Test for Alzheimer Biomarkers.
    JAMA. 2025 Jun 13. doi: 10.1001/jama.2025.9013.
    >> Share

    May 2025
  16. ANDERER S
    Knowing Alzheimer Disease Risk May Reduce Lifestyle Change Motivation.
    JAMA. 2025 May 30. doi: 10.1001/jama.2025.7764.
    >> Share

    January 2025
  17. MINTZKER Y
    Blood Biomarkers to Detect Alzheimer Disease.
    JAMA. 2025 Jan 23. doi: 10.1001/jama.2024.25294.
    >> Share

  18. PALMQVIST S, Hansson O
    Blood Biomarkers to Detect Alzheimer Disease-Reply.
    JAMA. 2025 Jan 23. doi: 10.1001/jama.2024.25297.
    >> Share

    September 2024
  19. DEVERKA PA, Lin GA, Phillips KA
    Payer Coverage Considerations for Alzheimer Disease Blood-Based Biomarker Tests.
    JAMA. 2024 Sep 30. doi: 10.1001/jama.2024.19084.
    >> Share

    August 2024
  20. RUBIN R
    A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke-Highlights From the AAIC.
    JAMA. 2024 Aug 16. doi: 10.1001/jama.2024.13816.
    >> Share

    July 2024
  21. PALMQVIST S, Tideman P, Mattsson-Carlgren N, Schindler SE, et al
    Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.
    JAMA. 2024 Jul 28:e2413855. doi: 10.1001/jama.2024.13855.
    >> Share

  22. SALLOWAY S, Rowe C, Burns JM
    Are Blood Tests for Alzheimer Disease Ready for Prime Time?
    JAMA. 2024 Jul 28. doi: 10.1001/jama.2024.12814.
    >> Share

  23. LU Y, Pike JR, Chen J, Walker KA, et al
    Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia.
    JAMA. 2024 Jul 28:e246619. doi: 10.1001/jama.2024.6619.
    >> Share

  24. HARRIS E
    FDA Greenlights Second Alzheimer Drug, Donanemab.
    JAMA. 2024 Jul 26. doi: 10.1001/jama.2024.13386.
    >> Share

    June 2024
  25. RUBIN R
    A Neurologist Learned He Had Alzheimer Disease 8 Years Ago-Here's What He Wants People to Know.
    JAMA. 2024 Jun 28. doi: 10.1001/jama.2024.10805.
    >> Share

    May 2024
  26. HARRIS E
    Study: 2 APOE4 Copies May Indicate Genetic Form of Alzheimer Disease.
    JAMA. 2024 May 31. doi: 10.1001/jama.2024.9649.
    >> Share

  27. THAMBISETTY M, Howard R
    Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering.
    JAMA. 2024 May 6. doi: 10.1001/jama.2024.7548.
    >> Share

    April 2024
  28. RUBIN R
    Could GLP-1 Receptor Agonists like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?
    JAMA. 2024 Apr 19. doi: 10.1001/jama.2024.1017.
    >> Share

    March 2024
  29. KO D, Pascual-Leone A, Shah SJ
    Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.
    JAMA. 2024 Mar 15. doi: 10.1001/jama.2024.2991.
    >> Share

  30. HARRIS E
    Biomarker Changes Can Begin 18 Years Before Alzheimer Disease Diagnosis.
    JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1568.
    >> Share

    February 2024
  31. HARRIS E
    Aducanumab Combined With Focused Brain Ultrasound More Effective.
    JAMA. 2024;331:466-467.
    >> Share

  32. HARRIS E
    Commercial Blood Test May Identify Alzheimer Disease Brain Pathology.
    JAMA. 2024 Feb 7. doi: 10.1001/jama.2024.0175.
    >> Share

    December 2023
  33. POMARA N, Imbimbo BP
    Use of Donanemab in Early Symptomatic Alzheimer Disease.
    JAMA. 2023;330:2304.
    >> Share

  34. EVANS CD, Sims JR
    Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
    JAMA. 2023;330:2304-2305.
    >> Share

    November 2023
  35. RAFII MS, Fortea J
    Down Syndrome in a New Era for Alzheimer Disease.
    JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22924.
    >> Share

    September 2023
  36. RUBIN R
    Who Should-and Can-Get Lecanemab, the New Alzheimer Disease Drug?
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.14443.
    >> Share

  37. ODOUARD IC, Socal MP, Anderson GF
    Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.17131.
    >> Share

  38. RUBIN R
    Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?
    JAMA. 2023 Sep 13. doi: 10.1001/jama.2023.17685.
    >> Share

    August 2023
  39. HARRIS E
    Study: Identifying Lewy Body Disease Before Symptoms.
    JAMA. 2023;330:686.
    >> Share

    July 2023
  40. HARRIS E
    MIND Diet No Better Than Control for Adults at Risk of Dementia.
    JAMA. 2023 Jul 26. doi: 10.1001/jama.2023.13134.
    >> Share

  41. HARRIS E
    Alzheimer Drug Lecanemab Gains Traditional FDA Approval.
    JAMA. 2023 Jul 19. doi: 10.1001/jama.2023.12548.
    >> Share

  42. SIMS JR, Zimmer JA, Evans CD, Lu M, et al
    Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    JAMA. 2023 Jul 17:e2313239. doi: 10.1001/jama.2023.13239.
    >> Share

  43. ROSENTHAL MB
    Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11702.
    >> Share

  44. MANLY JJ, Deters KD
    Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11704.
    >> Share

  45. RABINOVICI GD, La Joie R
    Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11703.
    >> Share

  46. WIDERA EW, Brangman SA, Chin NA
    Ushering in a New Era of Alzheimer Disease Therapy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11701.
    >> Share

  47. HARRIS E
    More Lean Muscle Might Reduce Alzheimer Disease Risk.
    JAMA. 2023 Jul 12. doi: 10.1001/jama.2023.12544.
    >> Share

    June 2023
  48. HARRIS E
    CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    JAMA. 2023 Jun 14. doi: 10.1001/jama.2023.10400.
    >> Share

  49. HARRIS E
    Brain Cell Biomarker for Preclinical Alzheimer Disease Identified.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9928.
    >> Share

    May 2023
  50. HARRIS E
    FDA Greenlights First Drug for Agitation Related to Alzheimer Disease.
    JAMA. 2023 May 24. doi: 10.1001/jama.2023.9153.
    >> Share

  51. MARCUS R
    New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines-Highlights From the 2023 American Academy of Neurology Conference.
    JAMA. 2023 May 10. doi: 10.1001/jama.2023.4389.
    >> Share

    March 2023
  52. HARRIS E
    Blood Biomarker Helps Distinguish Vascular Dementia.
    JAMA. 2023;329:969.
    >> Share

    February 2023
  53. HARRIS E
    Healthful Lifestyle May Slow Memory Loss, Even for APOE Gene Carriers.
    JAMA. 2023;329:622.
    >> Share

    October 2021
  54. EMANUEL EJ
    A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    JAMA. 2021;326:1367-1368.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016